What are Eli Lilly's main sources of revenue and its primary business segments?

Eli Lilly's primary business segment is pharmaceuticals, encompassing a wide range of products for human diseases. While it also has an animal health business, its operations are not material to the company's overall financial statements, meaning pharmaceuticals are the dominant revenue driver.

What are the key products that investors should be aware of, and what are the risks associated with them?

Key products mentioned include Prozac and Zyprexa in Neuroscience, Humulin, Humalog, ACTOS, and Evista in Endocrine, among others. A significant risk highlighted is the upcoming expiration of patents for several major drugs, most notably Prozac in the U.S. in February 2001. The company is actively engaged in litigation against generic manufacturers seeking to market their versions of these drugs, and an unfavorable outcome could materially impact financial results.

How is Eli Lilly positioned in terms of research and development (R&D), and what is its outlook?

Eli Lilly places a strong emphasis on R&D, investing $1.78 billion in 1999. The company believes its long-term competitiveness depends on discovering and developing innovative products. It focuses on therapeutic areas like central nervous system diseases, diabetes, infectious diseases, cancer, and cardiovascular diseases, and is also exploring biotechnology and genomics. Despite the R&D investment, the success of new products is inherently uncertain and takes many years to reach the market.

What legal challenges is Eli Lilly facing?

Eli Lilly is involved in several significant legal proceedings. These include extensive litigation concerning the patents for Prozac, challenges to product liability related to DES and Prozac, and numerous lawsuits alleging anti-competitive pricing practices related to discounts provided to managed-care organizations. While Lilly believes its actions have been lawful, these legal matters represent a potential financial risk.

LLY 10-K FY1999 Annual Report — Revenue, Net Income, EPS

Summary

Eli Lilly and Company's 2000 10-K filing for the fiscal year ended December 31, 1999, highlights its position as a leading pharmaceutical company focused on discovering, developing, manufacturing, and selling pharmaceutical products. The company's primary business segment is pharmaceuticals, with animal health operations being immaterial. Key product areas include neuroscience (Prozac, Zyprexa), endocrine (Humulin, Humalog, ACTOS, Evista), anti-infectives, cardiovascular agents, oncology products, and an antiulcer agent. Significant attention is given to intellectual property and patent protection, particularly concerning Prozac, with upcoming patent expirations and ongoing litigation against generic manufacturers. The company emphasizes its substantial investment in research and development, aiming to discover innovative products for unmet medical needs. Lilly also discusses its global operations, marketing strategies, and the competitive landscape, noting the impact of government regulations and cost-containment measures on its business.

Key Highlights

1Eli Lilly & Co. operates primarily in the pharmaceutical segment, with animal health being a minor contributor to financial statements.
2Key product lines include Neuroscience (Prozac, Zyprexa), Endocrine (Humulin, Humalog, ACTOS, Evista), Anti-infectives, Cardiovascular, and Oncology.
3The company is heavily invested in research and development, with $1.78 billion spent in 1999, focusing on areas like central nervous system diseases, diabetes, infectious diseases, cancer, and cardiovascular conditions.
4Prozac's U.S. compound patent expires in February 2001, and its method of use patent expires in December 2003, with ongoing litigation against multiple generic manufacturers challenging these patents.
5Other significant patent expirations for key drugs include Axid (2002), Zyprexa (2011), Humalog (2013), ReoPro (2015), Gemzar (2010/2012), and Evista (at least 2012).
6Lilly operates globally, with products sold in approximately 160 countries and manufacturing facilities in the U.S., Puerto Rico, and 28 other countries.
7The company is engaged in significant legal proceedings, including patent litigation for Prozac, product liability cases (DES, Prozac), and pricing litigation related to discounts to managed-care organizations.

ELI LILLY & Co Annual Report, Year Ended Dec 31, 1999

Summary

Key Highlights

Frequently Asked Questions